CT Sciences (Cancer Therapeutic Sciences) is a drug discovery company developing anti-cancer drugs that show significantly improved efficacy and substantially lower toxicity than current chemotherapeutic compounds. CT Sciences' proprietary liposome-encapsulation technology offers clear advantages over other available approaches. CT Sciences is currently focusing its research efforts on the development of two anti-cancer drugs for colorectal cancer. Both drugs are at the pre-clinical stage of development. In parallel, CT Sciences has developed a proprietary in vivo target-validation technology based on liposome encapsulation of viral-gene delivery vectors that allows the monitoring of drug delivery in living animal models. The company offers its technology as service- and license-based collaborations to biotechnology and pharmaceutical companies involved in cancer research.